[{"id":"54142a5f-7afe-4dbb-9986-c017cd62c728","acronym":"LNA-i-miR221","url":"https://clinicaltrials.gov/study/NCT04811898","created_at":"2021-03-23T11:52:19.811Z","updated_at":"2024-07-02T16:36:17.740Z","phase":"Phase 1","brief_title":"A Dose Escalation Study of LNA-i-Mir-221 for Cancer Treatment","source_id_and_acronym":"NCT04811898 - LNA-i-miR221","lead_sponsor":"Azienda Ospedaliera Universitaria Mater Domini, Catanzaro","biomarkers":" MIR221","pipe":"","alterations":" ","tags":["MIR221"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 01/14/2019","start_date":" 01/14/2019","primary_txt":" Primary completion: 12/29/2021","primary_completion_date":" 12/29/2021","study_txt":" Completion: 12/29/2021","study_completion_date":" 12/29/2021","last_update_posted":"2022-02-01"},{"id":"b1c01bc2-1c56-4c86-8abe-a664acc7f696","acronym":"","url":"https://clinicaltrials.gov/study/NCT02928627","created_at":"2021-01-18T14:23:04.239Z","updated_at":"2024-07-02T16:37:16.862Z","phase":"","brief_title":"Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in Hepatocellular Carcinoma","source_id_and_acronym":"NCT02928627","lead_sponsor":"University of Aberdeen","biomarkers":" MIR221 • MIR222","pipe":" | ","alterations":" miR-221 expression","tags":["MIR221 • MIR222"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e miR-221 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 06/01/2017","start_date":" 06/01/2017","primary_txt":" Primary completion: 12/10/2018","primary_completion_date":" 12/10/2018","study_txt":" Completion: 12/10/2018","study_completion_date":" 12/10/2018","last_update_posted":"2017-10-25"}]